Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.<\/p>\n
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.<\/p>\n
Eli Lilly (NYSE:LLY<\/a> | LLY Price Prediction<\/a>) and Pfizer (NYSE:PFE<\/a>) just gave investors two very different pharma stories. Lilly\u2019s latest quarter showcased runaway incretin demand and a raised outlook. Pfizer\u2019s showed a diversified book slowly stabilizing after COVID, with a fresh obesity bet stapled on. Heading into 2027, the question is whether uncapped growth or defensive transformation deserves your capital.<\/p>\n Mounjaro Runs the Table, Pfizer Steadies the Base<\/p>\n Lilly\u2019s Q2 2026 earnings report was category-defining. Revenue hit $22.97B, up 47.7% year over year, driven by Mounjaro at $9.94B (+91%) and Zepbound at $4.93B (+46%). International Mounjaro sales jumped 172% following China NRDL listing, a real signal that GLP-1 demand is global. CEO David Ricks called Lilly\u2019s future \u201cnever been brighter\u201d after 150 years, and management raised FY2026 revenue guidance to $85.0B to $87.0B.<\/p>\n Pfizer\u2019s Q1 2026 was quieter but more encouraging than skeptics expected. Revenue reached $14.45B, up 5.4%, with adjusted EPS of $0.75. Growth came from newer assets: Padcev at $591M (+39%), Nurtec at $353M (+42%), and oncology biosimilars at $409M (+55%). COVID drag continued, with Comirnaty down 59% and Paxlovid down 62%. Albert Bourla told investors Pfizer will \u201csuccessfully navigate this defining period\u201d, leaning on oncology and a late obesity push.<\/p>\n Uncapped Growth Versus Defensive Value<\/p>\n Lens Core Bet 2027 EPS Estimate Forward P\/E Dividend Yield Key Vulnerability Lilly is compounding off scarcity. Pfizer is engineering a floor with yield, biosimilars, and pipeline reinvestment. Both are legitimate strategies. They just answer different questions.<\/p>\n 2027 Catalysts Worth Marking on the Calendar<\/p>\n For Lilly, the swing factor is retatrutide\u2019s BLA filing in Q1 2027 across obesity, sleep apnea, and knee osteoarthritis pain. Analyst momentum reflects it: 19 upward EPS revisions versus 4 downward in the past 30 days for FY2027. I will watch whether new Indiana manufacturing capacity closes the persistent supply gap.<\/p>\n For Pfizer, the tests are Metsera\u2019s 10 pivotal starts in 2026, the Vyndamax exclusivity extended to June 2031, and Most-Favored-Nation pricing outcomes. You should also track whether oncology can keep offsetting primary-care softness.<\/p>\n Why I Would Park 2027 Capital in Lilly, With One Caveat<\/p>\n Personally, I lean Lilly for 2027. The incretin franchise is running ~$14.87B in a single quarter, retatrutide is queued, and analysts have marched EPS estimates higher. Shares are up 56.02% over the past year, so you are not buying it cheap. If you want a 6.22% yield and a lower entry multiple while a turnaround plays out, Pfizer fits. For anyone building a 2027 growth allocation, Lilly is the better place to park pharmaceutical capital, provided you can stomach the premium.<\/p>\n
\nLilly
\nPfizer<\/p>\n
\nIncretin dominance plus retatrutide BLA in Q1 2027
\n$7B Metsera obesity entry, oncology depth<\/p>\n
\n$47.34 avg, 27 analysts
\n$2.8970 avg, 25 analysts<\/p>\n
\n24x
\n9x<\/p>\n
\n0.56%
\n6.22%<\/p>\n
\nUS realized prices down ~9%, capacity limits
\n~$1.5B LOE headwind, obesity late<\/p>\n